 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 717824-30-1 |
| Molecular formula(MF) | C20H18FNO4 |
| Molecular Weight(MW): | 355.36 |
| Alias |
| In vitro | DMSO | 100 mg/mL warmed (281.4 mM) |
|---|---|---|
| Ethanol | 1 mg/mL warmed (2.81 mM) | |
| Water | <1 mg/mL | |
| In vivo | Suspended in water | 21mg/mL |
| Description | Vidofludimus is an orally active and potent dihydroorotate dehydrogenase (DHODH) inhibitor with IC50 of 134 nM for human DHODH. Phase 2. | ||
|---|---|---|---|
| Targets |
|
||
| In vitro |
Vidofludimus causes a concentration dependent inhibition of phytohemagglutinin-stimulated PBMC proliferation via the inhibition of pyrimidine de novo synthesis. [1] Vidofludimus attenuates IL-17 secretion from colonic strips by inhibition of STAT3 and NF-κB activation. [2] |
||
| In vivo | In MRLlpr/lpr mice, Vidofludimus (300 mg/kg, p.o.) reduces systemic autoimmunity and improves Lupus Nephritis. [1] In Rats, Vidofludimus (60 mg/kg, p.o.) effectively reduces macroscopic and histological pathology and the numbers of CD3+ T cells. [2] In a rat model of renal transplantation, Vidofludimus (20 mg/kg, p.o.) prolongs survival, paralleled by amelioration of histologic signs of acute rejection. [3] |